Home
Resources
Publications
Nebulisation of Dexamethasone Sodium Phosphate for the Treatment of Severe Asthmatic Horses

Nebulisation of Dexamethasone Sodium Phosphate for the Treatment of Severe Asthmatic Horses

S Mainguy-Seers, A Bessonnat, K Picotte, J-P Lavoie

Equine Vet J. 2019 Sep;51(5):641-645.

PMID: 30849189

Abstract:

Background:
Inhaled corticosteroids are effective in the treatment of equine asthma. A recent study reported that nebulisation of injectable dexamethasone had low systemic bioavailability in healthy horses and could represent a cost-effective therapy for equine inflammatory lung diseases.
Objectives:
To determine the effects of dexamethasone nebulisation on lung function in severe asthmatic horses. It was hypothesised that dexamethasone administered by nebulisation would be more effective than the same dose administered orally.
Study design:
Randomised blinded experimental study in severe asthmatic horses.
Methods:
Twelve severe asthmatic horses in clinical exacerbation were randomly assigned to treatment with 5 mg of dexamethasone sodium phosphate by nebulisation (n = 6) or by oral administration (n = 6), once daily for 7 days. Lung function was evaluated at baseline, after four treatment days (D4) and 24 h after the last dose (D8). The presence of residual bronchospasm was assessed on D8 with N-butylscopolammonium bromide administration (0.3 mg/kg i.v.). A respiratory clinical score was performed daily. Serum cortisol concentration was measured at baseline, D4 and D8.
Results:
The pulmonary elastance was unchanged in both groups while pulmonary resistance was significantly improved in the oral group on D8 (mean reduction in 1 cm H2 O/L/s [CI: 0.34-1.65, P = 0.003]). All horses had residual bronchospasm at the end of the study. There was a group difference in the respiratory clinical score as it was significantly reduced in the oral group, from D5 to D8. Serum cortisol concentration decreased in all subjects.
Main limitations:
Low number of horses and lack of placebo group.
Conclusions:
Considering the lack of improvement of lung function and the hypothalamic-pituitary-adrenal axis suppression, the results of this study do not support aerosolisation of an injectable form of dexamethasone for the treatment of severe equine asthma at the dose and with the nebuliser evaluated.

Chemicals Related in the Paper:

Catalog Number	Product Name	CAS Number	Price
AP2392394-B	Dexamethasone Sodium Phosphate	2392-39-4	Price
IAR42410206	L-Asparagine-15N2,d8		Price
IAR42410305	Glycerol-13C3, d8		Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: